AIM ImmunoTech Statistics
AIM ImmunoTech (HXB) Stock Statistics & Valuation Metrics
Total Valuation
AIM ImmunoTech has a market cap or net worth of EUR 5.35M. The enterprise value is -EUR 1.18M.
- Market Cap
- EUR 5.35M
- Enterprise Value
- -EUR 1.18M
Share Statistics
AIM ImmunoTech has 39,894,844 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 39,894,844
- Owned by Insiders
- 0.81%
- Owned by Institutions
- 0.13%
Financial Efficiency
AIM ImmunoTech’s return on equity (ROE) is 1.43 and return on invested capital (ROIC) is -313.55%.
- Return on Equity (ROE)
- 1.43
- Return on Assets (ROA)
- -2.41
- Return on Invested Capital (ROIC)
- -313.55%
- Return on Capital Employed (ROCE)
- 23.81
- Revenue Per Employee
- 4,631.579
- Profits Per Employee
- -734.63K
- Employee Count
- 19
- Asset Turnover
- 0.02
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of AIM ImmunoTech is -0.06. AIM ImmunoTech’s PEG ratio is -0.00.
- PE Ratio
- -0.06
- PS Ratio
- 62.95
- PB Ratio
- 0.66
- Price to FCF
- -0.80
- Price to Operating Cash Flow
- -0.66
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, AIM ImmunoTech had revenue of 88.00K and earned -13.96M in profits. Earnings per share was -8.62.
- Revenue
- 88.00K
- Gross Profit
- -250.00K
- Operating Income
- -10.53M
- Pretax Income
- -13.96M
- Net Income
- -13.96M
- EBITDA
- -12.94M
- Earnings Per Share (EPS)
- -8.62
Cash Flow
In the last 12 months, operating cash flow was -7.07M and capital expenditures -95,000, giving a free cash flow of -7.16M billion.
- Operating Cash Flow
- -7.07M
- Free Cash Flow
- -7.16M
- Free Cash Flow per Share
- -0.22
Dividends & Yields
AIM ImmunoTech pays an annual dividend of EUR 0.24, resulting in a dividend yield of ―
- Dividend Per Share
- EUR 0.24
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -125.24%
- Earnings Yield
- -303.43%
Stock Price Statistics
- Beta
- 1.16
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 6.09
- 200-Day Moving Average
- 6.09
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
AIM ImmunoTech upcoming earnings date is Aug 17, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 10, 2026
- Next Earnings Date
- Aug 17, 2027
- Ex-Dividend Date
- ―
Financial Position
AIM ImmunoTech as a current ratio of 0.53, with Debt / Equity ratio of -50.05%
- Current Ratio
- 0.53
- Quick Ratio
- 0.53
- Debt to Market Cap
- 2.58
- Net Debt to EBITDA
- -0.31
- Interest Coverage Ratio
- -12.96
Taxes
In the past 12 months, AIM ImmunoTech has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
AIM ImmunoTech EV to EBITDA ratio is 0.08, with an EV/FCF ratio of 0.13.
- EV to Sales
- -10.28
- EV to EBITDA
- 0.08
- EV to Free Cash Flow
- 0.13
- EV to Operating Cash Flow
- 0.13
Balance Sheet
AIM ImmunoTech has EUR 9.96M in cash and marketable securities with EUR 3.92M in debt, giving a net cash position of EUR 6.04M billion.
- Cash & Marketable Securities
- EUR 9.96M
- Total Debt
- EUR 3.92M
- Net Cash
- EUR 6.04M
- Net Cash Per Share
- EUR 0.15
- Tangible Book Value Per Share
- EUR 0.35
Margins
Gross margin is -3274.73%, with operating margin of -12800.00%, and net profit margin of -15526.37%.
- Gross Margin
- -3274.73%
- Operating Margin
- -12800.00%
- Pretax Margin
- -15526.37%
- Net Profit Margin
- -15526.37%
- EBITDA Margin
- -13170.33%
- EBIT Margin
- -14153.85%
Analyst Forecast
The average price target for AIM ImmunoTech is EUR 6.27, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 6.27
- Price Target Upside
- 2.86% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
